Table 4.
Sequencing analysis of liver cancers using EUS-FNA/FNB
| Year | References | Patient number | Cancer type | Sampling methods | Analysis methods | Analysis target | Success rate of sequencing analysis | Detection rate of actionable mutations |
|---|---|---|---|---|---|---|---|---|
| 2017 | Choi et al. [103] | 28 | HCC (4) | FNB | PNA-PCR | KRAS | 96.4% | 14.3% |
| IHCC (7) | Targeted seq | 57% | 25% | |||||
| MLC (16) | ||||||||
| Others (1) | ||||||||
| 2021 | Kai et al. [101] | 1 | IHCC (1) | FNA | Targted seq | MSI | 100% | 0% |
EUS endoscopic ultrasound, FNA fine-needle aspiration, FNB fine-needle biopsy, seq sequence, PNA peptide nucleic acid, PCR polymerase chain reaction, HCC hepatocellular carcinoma, IHCC intrahepatic cholangiocarcinoma, MLC metastatic liver cancer, MSI microsatellite instability